Completed OBSERVATIONAL NCT01679054

Cost-minimization Analysis of Gastric Cancer Treatments in Hong Kong

Cost-minimization Analysis of Xeloda® vs 5-fluorouracil-based Treatment for Gastric Cancer Patients in Hong Kong

Sponsor: Hoffmann-La Roche

Updated 7 times since 2017 Last updated: Aug 28, 2023 Started: Oct 31, 2011 Primary completion: Jul 31, 2012 Completion: Jul 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01679054, this observational or N/A phase trial focuses on Gastric Cancer and remains completed. Sponsored by Hoffmann-La Roche, it has been updated 7 times since 2011, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Apr 2024 — Jul 2024 [monthly]

Completed
Jan 2021 — Apr 2024 [monthly]

Completed

▶ Show 2 earlier versions

Apr 2018 — Jan 2021 [monthly]

Completed

Phase: NA → None
Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Oct 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hoffmann-La Roche
Pamela Youde Nethersole Eastern Hospital
Princess Margaret Hospital, Hong Kong
Vivian Wing Yan Lee

Data source: Chinese University of Hong Kong

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kowloon, Hong Kong